Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  BioMérieux    BIM   FR0013280286

BIOMÉRIEUX

(BIM)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

bioMérieux : Attractive price levels

share with twitter share with LinkedIn share with facebook
share via e-mail
09/12/2019 | 08:30am EDT
long trade
Live
Entry price : 70.6€ | Target : 76.4€ | Stop-loss : 66.28€ | Potential : 8.22%
bioMérieux shares are closing near attractive entry levels for a medium term horizon. Investors could regard the decline over the past weeks as a buying opportunity.
Investors have an opportunity to buy the stock and target the € 76.4.
Chart BIOMÉRIEUX
Duration : Period :
bioMérieux Technical Analysis Chart | MarketScreener
Full-screen chart
Summary
  • The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.

Strengths
  • The share is getting closer to its long-term support in weekly data, at EUR 66.28, which offers good timing for buyers.
  • The group usually releases upbeat results with huge surprise rates.
  • Over the last seven days, analysts have been revising upwards their EPS estimates for the company.
  • The stock is in a well-established, long-term rising trend above the technical support level at 66.28 EUR

Weaknesses
  • The firm trades with high earnings multiples: 29.19 times its 2019 earnings per share.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
Ratings chart
Subsector Diagnostic & Testing Substances
1st jan.Capitalisation (M$)Investor Rating
BIOMÉRIEUX22.09%9 181
DIASORIN46.82%6 198
AUTOBIO DIAGNOSTICS CO LTD70.61%4 950
NATERA INC134.67%2 297
GUANGZHOU WONDFO BIOTECH CO..--.--%2 210
MACCURA BIOTECHNOLOGY CO LT..--.--%1 959
-
NANOSTRING TECHNOLOGIES INC47.34%774
QUOTIENT LTD43.30%581
TELLGEN CORP--.--%535
VOLITIONRX LTD120.44%165
Autres valeurs du secteur

Jordan Dufee
© Zonebourse.com 2019
share with twitter share with LinkedIn share with facebook
share via e-mail

Disclaimer: The information, charts, data, views, or comments provided by SURPERFORMANCE SAS are intended for investors who have the necessary knowledge and experience to understand and appreciate the information contained within. These items are disseminated for personal reference only. They do not constitute an offer or solicitation to buy or sell financial products or services, nor an investment advice.
The use of the information disseminated takes place under the investor's sole responsibility, without recourse against SURPERFORMANCE SAS. SURPERFORMANCE SAS will not be liable, whether in contract, in tort, under any warranty, for errors, omissions, improper investments, or adverse evolution of markets.

Financials (EUR)
Sales 2019 2 648 M
EBIT 2019 392 M
Net income 2019 279 M
Debt 2019 218 M
Yield 2019 0,56%
P/E ratio 2019 29,7x
P/E ratio 2020 26,6x
EV / Sales2019 3,21x
EV / Sales2020 2,95x
Capitalization 8 291 M
Upcoming event on BIOMÉRIEUX
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 13
Average target price 74,00  €
Last Close Price 70,20  €
Spread / Highest target 19,7%
Spread / Average Target 5,42%
Spread / Lowest Target -12,3%
EPS Revisions
Managers
NameTitle
Alexandre Mérieux Chairman & Chief Executive Officer
Guillaume Bouhours Chief Financial Officer & Executive Vice President
Mark Miller Chief Medical Officer
Jean-Luc Bélingard Director
Michele Palladino Independent Director